Sharekhan`s research report on Cipla“Cipla reported a weaker performance in Q1FY2015, as reflected in a moderate 8% growth in net sales, a 754-BPS decline in the OPM and a 39% drop in the adjusted PAT. On a Y-o-Y basis the Q1 performance was weaker mainly because of a high base and the rationalisation process that is being implemented in different regions. Excluding the one-offs, the underlying sales growth stood near 15% during the quarter. The company also witnessed a stronger traction on a Q-o-Q basis, as reflected in an 8% growth in sales, a 370-BPS expansion in the margin and a 13% growth in the net profit.” “A healthy 17% growth in the Indian formulation market, winning of a new tender in South Africa, cutting of the working capital cycle by 20 days and the launch of two key products in Europe were a few positives of the quarter. The management has maintained its growth guidance of “mid-teen” sales growth and over 20% OPM for FY2015 which indicates H2FY2015 shall be stronger. We maintain our estimates but raise the price target by 5% to Rs495 (20x FY206E EPS). However, owing to a limited upside from the current levels, we downgrade our rating on the stock to Hold,” says Sharekhan research report.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
